spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  proteasome 

 HSMN NewsFeed - 4 Jan 2023
Monica Shaw appointed CEO of Oncopeptides - Jakob Lindberg assumes position as Chief Scientific Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 9 Dec 2022
Janssen Submits Biologics License Application to U.S. FDA for Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Jul 2022
Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO(R) (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 12 Jul 2021
Janssen Announces U.S. FDA Approval of DARZALEX FASPRO(R) (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Dec 2019
Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by Innovent and IASO BIO Presented at the 2019 ASH Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Feb 2019
U.S. FDA Approves DARZALEX(R) (daratumumab) Split-Dosing Regimen
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Oct 2018
FDA Approves KYPROLIS(R) (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone (Kd70) For Patients With Relapsed Or Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Aug 2018
Janssen Submits U.S. & EU Regulatory Applications Seeking Approval of DARZALEX(R) (daratumumab) Split Dosing Regimen
Biopharmaceuticals Oncology FDA Regulatory
 HSMN NewsFeed - 4 Apr 2018
Arvinas Completes $55 Million Series C Financing to Advance Protein Degradation Platform
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 30 Oct 2017
Kymera Therapeutics Announces Series A to Advance Novel Therapeutic Modality and Develop Innovative Therapies
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 20 Sep 2017
Arvinas Appoints Dr. John Houston as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Jul 2017
Kezar Life Sciences Announces Successful Completion of Phase 1a Study and Secures $50 Million in Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 24 Feb 2017
CHMP Issues Positive Opinion Recommending DARZALEX(R) (daratumumab) for Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 28 Nov 2016
Conditional Approval from the European Commission to Treat Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 22 Nov 2016
DARZALEX(R) (daratumumab) Approved by U.S. FDA in Combination with Two Standard of Care Regimens for the Treatment of Patients with Multiple Myeloma Who Have Received At Least One Prior Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Aug 2016
Takeda Receives Marketing Authorization in Canada for NINLARO(TM) (ixazomib) in Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 4 Jul 2016
European Commission Approves Extended Indication For Amgen's Kyprolis(R) (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma Patients
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 7 Jan 2016
C4 Therapeutics Enters Strategic Drug Discovery Collaboration in the Promising New Field of Targeted Protein Degradation
Biopharmaceuticals
 HSMN NewsFeed - 7 Jan 2016
C4 Therapeutics Launches with $73 Million Series A Financing
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 19 Nov 2015
Triphase Accelerator Corporation Announces FDA Orphan Drug Designation for Marizomib in Malignant Glioma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Oct 2015
Arvinas Secures $41.6M Series B Financing - Appoints New Board Members
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 22 Jun 2015
Vaxil's Lead Product ImMucin has Been Granted an Orphan Drug Designation by the FDA for the Treatment of Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Jun 2015
Kezar Life Sciences Closes $23M Series A Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 14 Apr 2015
Infinity Augments Executive Leadership Team, Appointing Chief Commercial Officer and General Counsel
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Sep 2014
OncoSec Medical Appoints Dr. Mai H. Le to Position of Chief Medical Officer and Names Dr. Robert H. Pierce as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Jun 2014
Takeda Announces Termination of Orteronel (TAK-700) Development for Prostate Cancer in Japan, U.S.A. and Europe
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 May 2014
Third Rock Ventures and The Column Group Launch Nurix with $25.1 Million Financing to Target Key Regulatory Pathway
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 8 Aug 2013
European Commission Approves VELCADE(R) as a Frontline Induction Therapy before Stem Cell Transplantation
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 2 Jul 2013
Warp Drive Bio Appoints Co-Founder Gregory Verdine, Ph.D., to Chief Executive Officer; Expands Team with Two Key Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Apr 2013
Cleave Biosciences Adds New Investor and $10 Million to Series A Financing
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 20 Jul 2012
Onyx Pharmaceuticals Receives FDA Accelerated Approval of Kyprolis(TM) (carfilzomib) for Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Nov 2011
FDA Approves Addition of Sustained Overall Survival Advantage (5-year follow-up) to Label for VELCADE(R) in Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Oct 2011
Onyx Pharmaceuticals and Bayer Healthcare Restructure Global Oncology Partnership
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Aug 2011
Onyx Pharmaceuticals Appoints Dr. Helen Torley as Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Feb 2011
Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Jan 2011
Karyopharm Therapeutics Inc. Appoints Michael Kauffman, MD, PhD, as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Oct 2010
Onyx Pharmaceuticals Provides Status Update on Carfilzomib
Biopharmaceuticals
 HSMN NewsFeed - 8 Sep 2010
Onyx Pharmaceuticals Announces Carfilzomib Development and Commercialization Agreement with Ono Pharmaceutical for Japan
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Jul 2010
Calithera Biosciences Closes $40 Million in Series A Financing
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 14 Jun 2010
Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 May 2010
Takeda to Co-Promote VELCADE(R) (bortezomib) for Injection in Japan
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jan 2010
FDA Approves Addition of Sustained Overall Survival Benefit to Label for VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 Dec 2009
Seattle Genetics and Millennium: The Takeda Oncology Company Announce Strategic Collaboration for Novel Late-Stage Lymphoma Program Brentuximab Vedotin (SGN-35)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Dec 2009
VELCADE(R) (Bortezomib) for Injection Based Combinations Deliver Two-Year Overall Survival Rates of Up to 88 Percent in Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Oct 2009
Proteolix, Inc. to be Acquired By Onyx Pharmaceuticals
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 12 Oct 2009
Onyx Pharmaceuticals to Acquire Proteolix, Inc.
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 18 Sep 2009
FDA Grants Priority Review Status to Supplement Containing Long-Term Survival Data for VELCADE(R) (bortezomib) for Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Sep 2009
FDA to Review Supplement Containing Long-Term Survival Data For VELCADE(R) (bortezomib) For Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Feb 2009
Proteolix Announces the Appointment of John Scarlett, M.D., President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Sep 2008
Proteolix Raises $79 Million in Series C Financing
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 8 Sep 2008
VELCADE(R) (Black Triangle Drug) (bortezomib) Approved For Previously Untreated Multiple Myeloma
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 28 Jul 2008
Millennium Advances Oncology Pipeline
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jul 2008
Repligen Elects Alfred L. Goldberg, Ph.D. to the Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 May 2008
Proteolix Appoints Thomas Kassberg Executive Vice President of Corporate Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Feb 2008
Proteolix Names Matthew Ferguson to Newly-Created Position of Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Aug 2007
Nereus Pharmaceuticals Raises $45 Million in Series D-2 Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 20 Mar 2007
Vidacare(R) Announces Sales and Marketing Leader for New Hematology/Oncology Business Unit
Devices Personnel
 HSMN NewsFeed - 17 Jan 2007
Proteolix Elects Dr. Michael Kauffman Chairman of the Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 4 Jan 2007
Avalon Pharmaceuticals Names Clinical Advisory Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Dec 2006
VELCADE(R) (Bortezomib) for Injection Demonstrates Substantial Activity Across Range of Lymphomas
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jun 2006
Nereus Pharmaceuticals Appoints Dr. Charles White as Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 May 2006
Proteolix Closes $45 Million Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 6 Mar 2006
Nereus Pharmaceuticals Closes Second Tranche of $42.6 Million Financing
Biopharmaceuticals Venture Capital
Return to NewsFeed  

 Additional items found! 34

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 34 additional stories matching:
proteasome
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.